tbuckley/cabot-search huggingface dataset:
Clinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancer
Authors: A. Robinson, S. Ellard, C. Speers, D. Turbin, E. Yorida, A. Rajput, T. Thomson, D. Huntsman, K. Gelmon
Journal: Journal of Clinical Oncology (2005)

500 Background: Trastuzumab based chemotherapy has dramatically altered the progression of metastatic breast cancer for patients with HER2/neu positive disease. However, not all patients will have significant response to trastuzumab based chemotherapy. Clinical and molecular predictors are needed to determine who will respond to trastuzumab based chemotherapy. Methods: Patients who received trastuzumab chemotherapy were identified from the BC Cancer Agency Pharmacy Database. Clinical factors were assessed from chart review and database extraction. Immunohistochemical (IHC) analysis was performed using tissue microarray (TMA), and we currently have EGFR, ER status, p53, and MIB-1 stained. We are going to be looking at PTEN, AKT, PR, HER3,and IGF-R as well. Outcomes were defined as sustained response (SR) or no response (NR) Logistic regression analyses were used to evaluate predictive significance of various clinical and IHC factors in outcome. Spearman correlation coefficients were used to determine correlations between factors. Results: We currently have clinical outcome information on 222 patients, and 114 patients with samples suitable for TMA analysis. SR are similar to NR in terms of factors such as disease free interval, estrogen receptor status, age, number of previous lines of chemotherapy and hormonal therapy, and presence or absence of visceral metastases. Patients with grade 2 tumours that were HER2 positive had significantly more sustained responses (45/67, 67%) than those who had grade 3 tumours (64/139, 46%) (p<0.05). We are currently preparing and analyzing tissue by microarray, and this will be presented at ASCO. On the first 75 patients, we have found no significant correlation between EGFR, ER, p53, and MIB-1 with outcome. Patients with positive p53 staining also were more likely to stain for MIB-1. Conclusions: Pathologic grade 2, HER2 positive tumors may have more sustained responses to trastuzumab based treatment than grade 3 tumors. Results on immunohistochemical profiling of 150 tumors treated with trastuzumab will be presented at the ASCO annual meeting. No significant financial relationships to disclose.
Abstract 17328: Frequency of Consumption of French Fries Is a Strong Predictor of Plasma Trans-Fatty Acids in Persons with Type 2 Diabetes
Authors: Dawn C Schwenke, John P Foreyt, Edgar R Miller, Rebecca Reeves, Mara Vitolins
Journal: Circulation (2011)

Trans -fatty acids (TFA) increase cardiovascular disease risk. However, relative contribution of foods to plasma TFA concentrations is unknown in persons with type 2 diabetes. We investigated how seven food sources of TFA (French fries, doughnuts, biscuits, nondairy creamer, chips, pretzels, and margarine on bread) were related to plasma 18-carbon TFA. Our population included persons randomized into Look AHEAD at two clinics (Baltimore, n=92; Houston, n=177) who participated in an ancillary study of oxidative stress and completed the Look AHEAD Food Frequency Questionnaire (LAFFQ). Look AHEAD is a multi-center controlled trial of lifestyle intervention for weight loss in overweight or obese adults (aged 45-75) with type 2 diabetes. Representation of women (57%) and minorities (18.6% AA, 8.2% Hispanic, 4.1% other race/ethnicity) was similar to Look AHEAD. TFA were measured before intervention in plasma collected between December 2002 and April 2004. Nutrients and eating frequency of food sources of TFA were determined from LAFFQ before intervention. In models with single sources of TFA adjusted for age, sex, race/ethnicity, clinic, sampling time, and plasma total fatty acid concentration, eating frequency of French fries (p&lt;0.01) and doughnuts (p=0.03) and margarine on bread (p=0.02) were significant predictors of log-transformed fasting plasma TFA (model R-square = 0.49 to 0.50) whereas eating frequency of biscuits, nondairy creamer, chips, and pretzels were not. Results were similar after further adjusting for body mass index, total dietary fat, dietary saturated fat, total calories, physical activity, serum insulin, and statin use. In a similarly adjusted model also mutually adjusting for all seven TFA sources (model R-square = 0.54), French fries was the only TFA food source that remained significantly associated with plasma log-transformed TFA (p&lt;0.005). Compared with ≤ once per month (lowest tertile), eating French fries ≥ twice per week (highest tertile) was associated with about 10% increase in log-transformed fasting plasma TFA. These results both emphasize the importance of continued efforts to reduce TFA in French fries and suggest frequency of eating French fries as a useful measure of modifiable TFA exposure.
Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute
Authors: V. Mohan, T. Chawla, K. Alzwahereh, W. Jeong, K. Y. Kita, V. S. Chua, A. Kalra, G. S. Rana, S. P. Chawla
Journal: Journal of Clinical Oncology (2008)

21506 Background: Trabectedin is a tris, tetrahydroisoquinoline alkaloid isolated from the marine ascidian Ecteinascidia turbinata. It is the first of a new class of antitumor agents with a mechanism of action that involves the transcription-dependent nucleotide excision repair system. It has recently received European Commission approval, as a second-line therapy, for soft tissue sarcoma (STS). This study was conducted from August 2005 to December 2007, as part of a Yondelis Expanded Access Program. Methods: Eighty-eight patients with advanced/metastatic STS were included in the analysis. Seventy-nine percent of patients included had failed or progressed on ≥2 lines of chemotherapy. Trabectedin was administered at 1.5 mg/m2 as a 24-hour IV infusion every 3 weeks. Disease assessment was performed every 2 courses as per Response Evaluation Criteria in Solid Tumors (RECIST). Results: Eighty patients were evaluated for response and toxicity. Partial response was obtained in 7 (9%) patients (5 leiomyosarcomas, 1 synovial sarcoma and 1 malignant fibrocystic histiocytoma), with disease control rate of 55%. At median follow-up of 46 weeks in partial responders, the median duration of partial response was 23 weeks. Stable disease lasting 6 or more months was seen in 20% patients. Progression-free survival at 6 months was 30%. Grade 3 and 4 hematologic toxicity was observed in 35% patients (neutropenia 30%, thrombocytopenia 15% and anemia 2.5%). A grade 3 laboratory transaminase elevation was seen in 17% patients with no grade 4 elevation, whereas grade 3 bilirubin elevation was observed in only 1 patient. All hepatic toxicities were transient except one which lasted > 6 weeks. Sixty percent of patients received white cell growth factors due to documented ANC < 1000/μL and 4.5% patients had neutropenic fever during treatment. Conclusions: Trabectedin is an active drug in advanced pre-treated STS patients. It has an acceptable and manageable toxicity profile. No significant financial relationships to disclose.
Abstract 1385: Prevalence of Anxiety and Type D Personality in an Outpatient ICD Clinic
Authors: Leo Pozuelo, Melanie Panko, Betty Ching, Denise Kosty-Sweeney, Karen Broer, Scott Bea, Sam Sears, Susanne Pedersen, Johan Denollet, Karl-Heinz Ladwig, Helmholtz Zentrum Munchen, Mina Chung
Journal: Circulation (2009)

Background:  ICD patients can exhibit significant psychosocial stress including anxiety. Type D personality, characterized by negative emotions and social inhibition, has been shown to negatively impact perceived quality of life and have an adverse effect in cardiovascular illnesses. We sought to measure the incidence of type D personality and the prevalence of overall anxiety in an ambulatory ICD population.   Methods:  To date 178 patients have been enrolled in a prospective study of anxiety in ICD patients, recruiting in the ICD device clinic at the Cleveland Clinic. Patients are enrolled at least 4 weeks after implantation of an ICD, seen in routine follow up, and administered the DS14 Type D questionnaire, from which the individual constructs of Negative Affectivity (NA) and Social Inhibition (SI) are also scored. The Beck Anxiety Inventory (BAI) was also administered, with total scores of 0 –9 correlating with no or low anxiety, 10 –18 mild to mod anxiety, 19 –29 mod-severe, and 30 – 63 severe anxiety. SPSS statistical software was used to calculate the collected data and interactions.   Results:  This outpatient population consisted of 74% males with a prevalence of 18 % type D that was equally distributed among gender. The mean BAI score was 7.1; 73% scored with no to low anxiety. Female patients had higher BAI anxiety scores (10.7 vs 5.8) compared to males (p   Conclusions:  In our ambulatory ICD population, overall anxiety rates were surprisingly   low  . The presence of Type D personality is a risk factor for increased anxiety. Screening for Type D personality may assist detecting at risk psychosocial ICD patients. Outcome studies of this patient population, including time from implantation and incidence of firings, warrant further study for quantification of overall ICD quality of life.
Abstract 1405: The Alpha-1A is the Predominant Alpha-1-Adrenergic Receptor in the Human Heart at the mRNA but not the Protein Level
Authors: Brian C Jensen, Philip M Swigart, Bat-Erdene Myagmar, Sanjay Shah, Teresa DeMarco, Charles Hoopes, Paul C Simpson
Journal: Circulation (2007)

Background: Alpha-1-adrenergic receptors (ARs) play an adaptive role in the heart and protect against the development of HF. There are three alpha-1-AR subtypes: A, B, and D. Limited prior studies find that the human heart contains primarily the A subtype mRNA. Alpha-1-AR subtype proteins have never been measured in human heart. Hypothesis: This study tests the hypothesis that all three alpha-1-AR subtypes are present in both the failing (F) and non-failing (NF) human heart. Methods: F human hearts [n =6, mean EF 26%, mean age 47, 3 males (M), 3 females (Fe)] were obtained after cardioplegia during heart transplant. NF controls were unused donor hearts (n =6, mean EF 58%, mean age 41, 4 M, 2 Fe). Left (LV) and right ventricular (RV) tissue from the mid free wall was flash frozen in liquid nitrogen. mRNA was purified and treated with DNase. Quantitative real time reverse transcription PCR results were normalized to beta-actin and TATA binding protein. Saturation binding used tritiated prazosin and competition binding used 5-methylurapidil, an alpha-1A-specific antagonist. Results: All three alpha-1-AR subtype mRNAs were identified, and the A subtype was the most abundant in both LV and RV (p &lt;0.05). Subtype mRNA levels did not change significantly in F versus NF, in either LV or RV [see table . Arbitrary Units ±SEM (% of total alpha-1-AR mRNA )]. Mean alpha-1-AR protein density was unchanged in HF by saturation binding (NF: 4.6 ±0.7 fmol/mg vs. F: 3.9 ±0.8 fmol/mg). Competition binding in NF LV tissue (n =6) showed a classic two-site binding curve with 38% high affinity (alpha-1A) binding sites and 62% low affinity (alpha-1B/D) sites. Conclusions: These results are the first to measure alpha-1-AR subtype proteins in the human heart. At the protein level, alpha-1A is less abundant than the sum of alpha-1B and D, even though alpha-1A mRNA is most abundant. Given that alpha-1-ARs protect against HF in animal models, specific activation of cardiac alpha-1-AR subtypes might be feasible.
Abstract 5932: The Differences of Echocardiography and MRI Findings in Patients with Constrictive Pericarditis According to the History of Chest Radiation
Authors: Kye Hun Kim, DaLi Feng, James Glockner, Matthew Martinez, William D Edwards, Imran S Syed, Philip Araoz, Paul R Julsrud, Jerome F Bree, Eric Williamson, Jae K Oh
Journal: Circulation (2008)

Background: Radiation therapy (RT) to the chest may induce various combined cardiac problems such as constrictive pericarditis (CP), restrictive myocardial disease, and coronary artery disease. Therefore, it was hypothesized that the MRI and transthoracic echocardiographic (TTE) findings in patients with CP may differ according to the history of RT. Methods: A total of 68 patients with CP who performed both TTE and MRI study at Mayo Clinic from 2002 to 2008 were reviewed and divided into two groups according to the history of RT; RT group (group I, n=13, 53.6±9.8 years, 8 males) versus no RT group (group II, n=55, 59.0±14.8, 45 males). Results: The results of TTE study were summarized in table . Early diastolic velocity of septal mitral annulus (E′) and deceleration time (DT) of mitral inflow was significantly lower, and the ratio of early diastolic mitral inflow velocity (E) to E′ is significantly higher in group I than in group II. Left atrial volume index (LAVI) was significantly lower and LA area and left ventricular end-diastolic dimension (LVEDD) was significantly smaller in group I than in group II. Delayed enhancement of pericardium was the only significant finding in MRI and significantly prevalent in group I than in group II (100.0% in group I vs 63.6% in group II, p=0.012). The other MRI findings including pericardial thickness, left ventricular and right ventricular ejection fraction, and the presence of pericardial and pleural effusion were not different between the groups. Conclusion: In CP patients with the history of RT compared to patients without history of RT, E′ and DT was significantly lower, LAVI and LVEDD were smaller, pericardial DE in MRI was invariably found. The lower E′ velocity and decreased chamber size and volumes may be explained by RT induced coexisting myocardial disease. TTE findings of the patients
Adapting molecular inversion probe (MIP) technology for allele quantification in childhood leukemia
Authors: J. D. Schiffman, K. M. Welch, R. Davis, G. V. Dahl, N. J. Lacayo, M. Faham, J. M. Ford, H. Ji
Journal: Journal of Clinical Oncology (2007)

9530 Background: Leukemia accounts for ∼40% of newly diagnosed pediatric malignancies, and relapsed leukemia is the leading cause of death in childhood cancer. Genomic instability events contribute to neoplastic development and have been used to classify and risk stratify non-leukemic adult and pediatric tumors. Analyzing leukemic blasts for gene copy changes with advanced molecular techniques could prove useful in further risk stratifying and developing new treatment strategies for pediatric leukemia. Methods: Molecular Inversion Probes (MIPs) analyze genetic target sequences in parallel with high specificity and sensitivity at the highest genomic resolution, and were originally designed for single nucleotide genotyping. The MIP assay was adapted to analyze both gene copy number and loss of heterozygosity (LOH) events in pediatric leukemia samples (pre-B ALL, T-ALL, AML). DNA was extracted (100 ng) from paired bone marrow (diagnosis) and peripheral blood (remission) samples (n = 40). The MIP assay was run with a customized Affymetrix 20K Cancer Panel (representing oncogenes, tumor suppressor, DNA repair, cell growth, and metabolism genes). Gene copy number changes were identified by comparing probe signal intensity between leukemia samples and normal cell-lines. LOH events were determined by identifying genotype changes between matched leukemic and remission samples. Results: Each sample had unique patterns of multiple gene copy changes and LOH events distributed across all chromosomes. Additionally, samples were found to have overlapping copy number changes and LOH regardless of leukemia type. AML samples had fewer LOH events and could be separated by unsupervised clustering from the other leukemia samples. Conclusions: MIPs represent novel genotyping technology that can be adapted for gene copy analysis of childhood leukemia. Unique and distinguishing signatures of allelic imbalance can be determined between ALL and AML clinical samples using MIP technology. The unexpected overlap of LOH and deleted genes may represent a common molecular mechanism that requires further investigation. No significant financial relationships to disclose.
Standard Methods of the Division of Laboratories and Research of the New York State Department of Health. General Laboratory Procedures and the Methods Used in the Department for the Preparation of Media and Glassware, the Laboratories for Sanitary and Analytical Chemistry, the Research, Publications, and Library Department, the Antitoxin, Serum, and Vaccine Laboratories, the Diagnostic Laboratories, the Executive Offices.
Authors: Augustus Baldwin Wadsworth
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16590: Incremental Value of Routine Preoperative Echocardiography in Patients Undergoing Coronary Artery Bypass Surgery: The Pre-Operative Surgical Stratification by Echocardiography (POSSE) Study
Authors: Jonathan Afilalo, Aidan Flynn, Arvind K Agnihotri, Cristina Castrillo, Melissa Bendayan, David M Shahian, Michael H Picard
Journal: Circulation (2011)

Background: Although echocardiography is commonly performed before coronary artery bypass surgery (CABG), there has yet to be a study examining the prognostic value of a comprehensive echocardiogra...
Abstract 019: Association between Vitamin D and Cardiovascular Events: The Heart and Soul Study
Authors: Christine C Welles, Mary A Whooley, Ananth Karumanchi, Ravi Thadhani, Anders Berg, Joachim H Ix, Kenneth J Mukamal
Journal: Circulation (2013)

Background: A growing body of evidence indicates that vitamin D deficiency is associated with adverse cardiovascular (CV) outcomes. It is unclear whether vitamin D deficiency is simply a marker of ...
Treatment of Atrial Fibrillation
Authors: Eric N. Prystowsky, Benzy J. Padanilam
Journal: Journal of the American College of Cardiology (2015)

The incidence and prevalence of atrial fibrillation (AF) are increasing globally, and the arrhythmia has profound impact on patient outcomes [(1)][1]. The precise reasons for the rising AF epidemic are unclear, and proposed causes include the aging population and increased incidence of risk factors
Human Sterility: Causation, Diagnosis, and Treatment. A Practical Manual of Clinical Procedure
Authors: Samuel Raynor Meaker
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recurrent Mutations within the Nfkbie gene: A Novel Mechanism for NF-κB Deregulation in Aggressive Chronic Lymphocytic Leukemia
Authors: Larry Mansouri, Lesley-Ann Sutton, Viktor Ljungstrom, Sina Bondza, Linda Arngarden, Sujata Bhoi, Jimmy Larsson, Diego Cortese, Antonia Kalushkova, Rebeqa Gunnarsson, Emma Young, Elin Falk-Sorqvist, Karla Plevova, Alice Muggen, Xiao-Jie Yan, Birgitta Sander, Gunilla Enblad, Karin E Smedby, Gunnar Juliusson, Chrysoula Belessi, Nicholas Chiorazzi, Jonathan C Strefford, Anton W Langerak, Sarka Pospisilova, Frederic Davi, Mats Hellstrom, Helena Jernberg Wiklund, Paolo Ghia, Ola Soderberg, Kostas Stamatopoulos, Mats Nilsson, Richard Rosenquist
Journal: Blood (2014)
A phase I study of intravesical Ad-IFN in superficial bladder cancer patients
Authors: C. P. Dinney, W. F. Benedict, D. L. Cutler, M. F. Fisher, M. A. O'Donnell
Journal: Journal of Clinical Oncology (2009)

e16048 Background: Intravesical BCG (Bacillus Calmette-Guérin) is the gold standard for treatment of superficial bladder cancer. Recurrence is a significant problem. Intravesical interferon α (IFN) demonstrated complete response (CR) in ∼40% patients with most relapsing &lt;1 year. Intravesical Ad-IFN takes advantage of the bladder to allow prolonged exposure to high concentrations of IFN; this is expected to potentiate durable therapeutic responses. Syn3 is an excipient used to increase adenoviral vector (Ad) transfection. Methods: The phase I study is a nonrandomized, open-label, rising-dose, multi-center study of Ad-IFN in patients with papillary bladder cancer, or carcinoma in situ refractory to BCG. Patients with T1 were not enrolled unless they refused cystectomy. A minimum of 3 subjects were enrolled at each dose level. Adverse events and lab abnormalities were graded according to CTC version 3 criteria. The occurrence of treatment-related Grade 3 or Grade 4 toxicity is considered dose-limiting toxicity (DLT). The maximum tolerated dose is defined as the dose which results in DLT in ≤1/6 subjects. Urine from pre-treatment, posttreatment days 0–7, 10, 14, and 28 were tested for IFN, Syn3, Ad-IFN DNA, and research biomarkers. Blood was assayed for IFN, Syn3, Ad-IFN DNA, anti- adenovirus and anti-IFN antibodies. Results: Intravesical administration of 3×10 9 , 1×10 10 , 3x10 10 , 1×10 11 , or 3×10 11 particles/ml of Ad-IFN (75ml) in 1mg/ml Syn3 is safe with only minor initial urgency controlled with anticholinergic medication. Of the 13 evaluable patients, 6 are CR, defined as a negative cytology and biopsy at 3 months. CR patients were offered a second dose. Response duration is variable with longest &gt;1 year. Urinary IFN was seen for all patients in a dose-dependent fashion. TRAIL, IP-10, M65, and M30 were also seen. Conclusions: Initial safety and response activity justify further clinical development. [Table: see text]
Abstract 14713: MicroRNA-155 Upregulation Mediates Sepsis-Associated Cardiovascular Dysfunction
Authors: Francisco Vasques-NOvoa, Catarina Quina-Rodrigues, Rui Cerqueira, LuIs MendonCa, Paulo Castro-Chaves, Andre P LourenCo, Adelino F Leite-Moreira, Roberto Roncon-Albuquerque
Journal: Circulation (2012)

Background: Sepsis-associated cardiovascular dysfunction remains a leading cause of death in critically ill patients. MicroRNA-155 (miR-155) targets important transcripts in inflammation and cardio...